Wegovy Oral Starting Dose
There is no oral formulation of Wegovy approved by the FDA. Wegovy (semaglutide) is only available as a subcutaneous injection, not as an oral medication 1.
Critical Clarification
You may be confusing two different products:
- Wegovy: Subcutaneous injection for weight management (starting dose 0.25 mg weekly)
- Oral semaglutide (Rybelsus): Oral tablet approved only for type 2 diabetes, NOT for weight management
If You Mean Subcutaneous Wegovy
The starting dose is 0.25 mg injected subcutaneously once weekly for 4 weeks 1. This is followed by a structured dose escalation schedule:
- Weeks 1-4: 0.25 mg once weekly
- Weeks 5-8: 0.5 mg once weekly
- Weeks 9-12: 1 mg once weekly
- Weeks 13-16: 1.7 mg once weekly
- Week 17 onward: 2.4 mg once weekly (recommended maintenance) or 1.7 mg once weekly
This gradual titration reduces gastrointestinal adverse reactions 1.
If You Mean Oral Semaglutide (Rybelsus)
Oral semaglutide is NOT approved for weight management or obesity treatment 2. It is only FDA-approved for glycemic control in type 2 diabetes at doses of 7 mg and 14 mg daily 3.
For diabetes management, the starting dose is 3 mg once daily for 30 days, taken at least 30 minutes before the first food, fluid, or other oral medications of the day with no more than 120 mL of plain water 2.
Important Administration Details for Oral Semaglutide (if prescribed for diabetes):
- Must be taken on an empty stomach
- At least 30 minutes before any food or other medications
- With no more than 120 mL (4 oz) of plain water only
- After 30 days on 3 mg, increase to 7 mg daily
- Can further increase to 14 mg daily after another 30 days if needed for glycemic control
Common Pitfall
Do not confuse investigational higher-dose oral semaglutide (25 mg, 50 mg) studied for obesity with currently approved formulations 3, 4. While oral semaglutide 50 mg showed efficacy for weight loss in the OASIS-1 trial (17.1% weight reduction), this formulation is not yet FDA-approved 3.